Victoza (liraglutide): What It Is, Trial History and Regulatory Status

Evidence tier: Established (FDA-approved; multiple randomized controlled trials).

Victoza is a brand name for liraglutide, an injectable glucagon-like peptide-1 (GLP-1) receptor agonist marketed by Novo Nordisk. It is a prescription medicine, not an experimental or investigational substance, and it has been on the United States market since 2010. This page summarises what the published literature and the regulatory record describe about the product: what the molecule is, the trial programme behind its approval, the adverse events that appear in the label and in published case reports, and how Victoza differs from other products that contain the same active ingredient. This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication.

What Victoza Is

Active ingredient and drug class

The active ingredient in Victoza is liraglutide, a synthetic analogue of the human incretin hormone GLP-1. Liraglutide shares most of the amino-acid sequence of native GLP-1 but carries a fatty-acid side chain that binds reversibly to albumin, which slows its clearance compared with the native hormone. The United States prescribing information describes Victoza as a subcutaneous injection administered once daily, independently of meals, with the dose determined by the prescriber according to the label's titration schedule.

Pharmacologically, liraglutide belongs to the GLP-1 receptor agonist class, which also includes exenatide, dulaglutide, lixisenatide and semaglutide. These agents differ in molecular structure, half-life and approved indications, so findings for one are not automatically transferable to another.

How liraglutide is described to work

The Victoza prescribing information states that liraglutide activates the GLP-1 receptor, increases insulin secretion in a glucose-dependent manner, suppresses inappropriately high glucagon secretion and slows gastric emptying. Because insulin release through this pathway depends on prevailing glucose concentrations, the label notes that liraglutide alone is not expected to cause hypoglycaemia to the same degree as insulin secretagogues, although the risk rises when it is combined with sulfonylureas or insulin.

Beyond the label, laboratory work has examined where and how liraglutide acts. A 2014 mouse study published in the Journal of Clinical Investigation reported that the hypothalamic arcuate nucleus mediated liraglutide-dependent weight loss, implicating central rather than purely peripheral signalling (PMID 25202980). Building on that, researchers reported in Cell Metabolism in 2022 that tanycytes — specialised cells lining the hypothalamic third ventricle — controlled hypothalamic liraglutide uptake and its anti-obesity actions in rodents (PMID 35716660). A 2025 pharmacology study reported that activation of cyclooxygenase-2 signalling mediated liraglutide-induced lipolytic activity in adipose tissue (PMID 40935112). These were mechanistic animal and cell experiments; they describe candidate pathways rather than clinical outcomes in people.

Manufacturer

Victoza is manufactured and marketed by Novo Nordisk. Following patent expiry, generic and authorized-generic liraglutide injection products have also been approved in the United States, which means a pharmacy may dispense a liraglutide product that is not branded Victoza depending on local substitution rules and the prescription written.

Approved Indications and Approval Timeline

The regulatory record for liraglutide in the United States spans more than a decade and covers two distinct brand families. The table below summarises the milestones most often referenced in the label and in FDA announcements.

Victoza is not approved as a weight-loss medicine. The label states that it has not been studied in patients with a history of pancreatitis and that it is not indicated for type 1 diabetes or for the treatment of diabetic ketoacidosis. Whether any of these indications applies to an individual is a clinical judgement for a licensed prescriber.

Trial History as Published

The programme that supported approval

Liraglutide reached the market through a structured programme of randomised controlled trials rather than a single study. The diabetes programme — widely referred to in the literature as the LEAD (Liraglutide Effect and Action in Diabetes) trials — consisted of randomised, multicentre studies in adults with type 2 diabetes, using change in glycated haemoglobin (HbA1c) from baseline as the primary endpoint and comparing liraglutide with placebo or with active comparators such as glimepiride, rosiglitazone, insulin glargine, sitagliptin and exenatide, in monotherapy and add-on designs. Secondary endpoints across those trials typically included fasting plasma glucose, body weight, proportion of participants reaching HbA1c targets, hypoglycaemia rates and gastrointestinal tolerability.

The cardiovascular indication rested on a large randomised, double-blind, placebo-controlled cardiovascular outcomes trial in adults with type 2 diabetes at high cardiovascular risk, with a primary composite endpoint of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, published as the LEADER trial. The paediatric indication rested on a randomised, double-blind, placebo-controlled trial in children and adolescents with type 2 diabetes, published as the ELLIPSE trial, again with change in HbA1c as the primary endpoint. A separate randomised programme, published as the SCALE trials, supported the higher-dose weight-management product rather than Victoza.

Why this page does not quote those trial numbers

PeptideU cites only sources it has verified. The primary LEAD, LEADER, ELLIPSE and SCALE publications are not among the verified sources for this page, so no effect sizes, event rates or percentage changes from those trials are reproduced here. Readers looking for the numerical results can consult the FDA-approved prescribing information for Victoza, which contains the clinical-studies section, or the original journal reports, and can discuss what those numbers mean for an individual situation with a prescriber. Stating the design and endpoints, as above, describes what was measured without asserting a result that this page has not verified.

Mechanistic and disease-model literature since approval

Post-approval laboratory work has continued to explore liraglutide's biology in animal and cell models. In a 2023 study in Molecular Medicine, researchers reported that liraglutide attenuated type 2 diabetes-associated non-alcoholic fatty liver disease in experimental models by activating AMPK/ACC signalling and inhibiting ferroptosis (PMID 37770820). A 2024 study in Advanced Science reported that liraglutide promoted diabetic wound healing through a Myo1c/Dock5 pathway (PMID 39159301), and a 2024 immunopharmacology study reported that liraglutide alleviated ferroptosis in renal ischaemia-reperfusion injury by inhibiting macrophage extracellular trap formation (PMID 39340991).

Cardiac models have also been examined. A 2025 report in Life Sciences described liraglutide attenuating doxorubicin-induced cardiomyocyte ferroptosis via DHHC7-mediated STAT3 palmitoylation (PMID 40819789), and a 2025 report in Scientific Reports described liraglutide attenuating autoimmune myocarditis by inhibiting NLRP3 and NF-\u03baB pathways (PMID 40715315). None of these findings is an approved indication, and preclinical signals frequently fail to reproduce in human trials. They are included here because they describe the direction of current laboratory interest, not because they support any clinical use.

Adverse Events: What Studies Report

Label-level adverse reactions and warnings

The Victoza prescribing information lists gastrointestinal effects as the most common adverse reactions, including nausea, vomiting, diarrhoea, constipation, dyspepsia and decreased appetite, and notes headache and injection-site reactions. Labelled warnings and precautions include pancreatitis, acute gallbladder disease, hypoglycaemia when used with an insulin secretagogue or insulin, acute kidney injury (including cases associated with dehydration from vomiting or diarrhoea), hypersensitivity reactions and increased heart rate. The label also carries a boxed warning concerning thyroid C-cell tumours, discussed in the regulatory section below.

Published case reports

Beyond aggregate trial data, the peer-reviewed literature contains individual case reports that describe adverse events temporally associated with liraglutide. Clinicians reported a case of liraglutide-induced acute pancreatitis in 2014 (PMID 25327099), and a 2022 report in Cureus described acute pancreatitis following a liraglutide overdose (PMID 35228970). Gallbladder events have also been described: a 2015 report in Aging Clinical and Experimental Research described liraglutide-related cholelithiasis (PMID 25725635). A 2018 Cureus case report described liraglutide-induced acute gastroparesis, an extreme presentation of the delayed gastric emptying that the drug class produces pharmacologically (PMID 30868005).

Case reports describe single patients. They cannot establish how often an event occurs, and they cannot prove causation, because confounding conditions, concomitant medicines and chance timing are all possible explanations. Their value is signal generation: they tell clinicians what to watch for. Anyone experiencing severe abdominal pain, persistent vomiting, signs of dehydration or other concerning symptoms while prescribed a GLP-1 receptor agonist would need to contact a licensed clinician promptly rather than consult a web page.

Regulatory Status, Boxed Warning and Label Facts

Boxed warning

The Victoza label carries a boxed warning for the risk of thyroid C-cell tumours, based on findings in rodent carcinogenicity studies; the label states that human relevance has not been determined. Victoza is contraindicated, per the label, in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2. The label also states it is contraindicated in patients with a prior serious hypersensitivity reaction to liraglutide. These are prescribing decisions that sit with a licensed physician who knows the patient's history.

Prescription status, shortages and compounding

Liraglutide products are prescription-only in the United States and in most other jurisdictions. GLP-1 receptor agonist products have appeared on FDA's publicly maintained drug shortages database in recent years as demand shifted across the class; that database is the authoritative place to check the current status of any particular presentation, because listings change.

On compounding, the general statutory framework under the Federal Food, Drug, and Cosmetic Act is that compounders operating under sections 503A and 503B may not compound a drug that is essentially a copy of a commercially available approved drug, with limited exceptions such as when a drug appears on FDA's shortage list or when a documented clinical difference for an individual patient is established. FDA has publicly cautioned that compounded GLP-1 products are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing. Nothing on this page is legal advice; questions about the legal status of a specific product belong with a qualified attorney, a pharmacist or the relevant regulator.

How Victoza Differs From Other Liraglutide Products

Several distinct products contain liraglutide, and they are not interchangeable. The differences lie in the strength of the pen, the titration schedule in the label, the approved indication and, in one case, a co-formulated insulin.

Two further distinctions matter for readers comparing products. First, semaglutide (marketed as Ozempic, Wegovy and Rybelsus) and tirzepatide (Mounjaro, Zepbound) are different molecules with different labels and different trial programmes; liraglutide data do not transfer to them. Second, Victoza and Saxenda contain the same active ingredient but are approved for different purposes and are labelled differently, so a prescriber's choice between them reflects the indication being treated rather than a preference between brands.

Consulting a Prescriber

Nothing on this page can substitute for an individual clinical assessment. Whether a GLP-1 receptor agonist is appropriate depends on factors that only a prescriber can weigh, including kidney function, pancreatic and gallbladder history, thyroid and family history, pregnancy status, other medicines (particularly insulin and sulfonylureas), and the specific goal of treatment. Questions a reader might reasonably raise with a clinician include which indication applies to their situation, what monitoring the label recommends, how the labelled warnings intersect with their own medical history, and what published trial results mean in their context. This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication.

PeptideU is not affiliated with or endorsed by Novo Nordisk. Victoza is a trademark of its owner. This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication.

References

• The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss (The Journal of Clinical Investigation, 2014)
• Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions (Cell Metabolism, 2022)
• Activation of cyclooxygenase-2 signaling mediates liraglutide-induced adipose lipolytic activity (European Journal of Pharmacology, 2025)
• Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis (Molecular Medicine, 2023)
• Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5 (Advanced Science, 2024)
• Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation (International Immunopharmacology, 2024)
• Liraglutide attenuates doxorubicin-induced cardiomyocyte ferroptosis via DHHC7-mediated STAT3 palmitoylation (Life Sciences, 2025)
• Liraglutide attenuates autoimmune myocarditis by inhibiting NLRP3 and NF-\u03baB pathways (Scientific Reports, 2025)
• Liraglutide-induced acute pancreatitis (The Journal of the Association of Physicians of India, 2014)
• Liraglutide Overdose-Induced Acute Pancreatitis (Cureus, 2022)
• Liraglutide-related cholelithiasis (Aging Clinical and Experimental Research, 2015)
• Liraglutide-induced Acute Gastroparesis (Cureus, 2018)